Shanghai New World Co Ltd

Shanghai New World Co Ltd maintains a relatively strong liquidity position, with a current ratio of 1.6, indicating the company can cover its short-term liabilities with its short-term assets. However, the company has a negative net cash position after subtracting total debt, which raises liquidity concerns. The debt-to-equity ratio of 0.13 suggests a conservative capital structure, with limited leverage. In terms of profitability, the company's return on equity (ROE) is 1.58%, and its return on assets (ROA) is 1.16%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The net income of 66.65 million CNY and operating income of 78.94 million CNY indicate modest profitability, with a net margin of approximately 6.05%. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of regulatory or market disruptions in its primary operating region. Looking ahead, the company's revenue is expected to grow, with the most recent actual revenue reported at 1.04 billion CNY. However, the capital expenditure of -159.11 million CNY suggests a reduction in investment, which may impact long-term growth potential. The company's free cash flow of 15.63 million CNY is relatively low, indicating limited capacity for reinvestment or shareholder returns. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company has not disclosed any imminent plans for share issuance or dilution, and its diluted shares outstanding are equal to its basic shares, suggesting no near-term dilution pressure. However, the negative net cash position remains a concern for liquidity management. Recent financial filings and disclosures have not revealed any material events or strategic shifts that would significantly alter the company's trajectory. The company continues to operate within its core pharmaceuticals business, with no new product lines or major partnerships disclosed in the latest available data.